| Anemia in chronic kidney disease
Mircera vs Jesduvroq
Side-by-side clinical, coverage, and cost comparison for anemia in chronic kidney disease.Deep comparison between: Mircera vs Jesduvroq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJesduvroq has a higher rate of injection site reactions vs Mircera based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Jesduvroq but not Mircera, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Mircera
Jesduvroq
At A Glance
SC or IV injection
Every 2-4 weeks
Erythropoiesis-stimulating agent (ESA)
Oral
Daily
HIF-PH inhibitor
Indications
- Anemia in chronic kidney disease
- Anemia in chronic kidney disease
Dosing
Anemia in chronic kidney disease (adult, on dialysis) Initial: 0.6 mcg/kg IV or SC once every 2 weeks; once hemoglobin is stabilized, may convert to once monthly at twice the every-2-week dose.
Anemia in chronic kidney disease (adult, not on dialysis) Initial: 1.2 mcg/kg SC once monthly, or 0.6 mcg/kg IV or SC once every 2 weeks; may convert to once monthly at twice the every-2-week dose once hemoglobin is stabilized.
Anemia in chronic kidney disease (pediatric, ESA conversion) IV or SC once every 4 weeks (ages 3 months to 17 years); starting dose based on prior weekly ESA dose per conversion table; patients requiring < 30 mcg should not be treated with Mircera.
Anemia in chronic kidney disease (ESA-naive, on dialysis) Once daily oral; starting dose 4 mg if hemoglobin <9 g/dL, 2 mg if >=9 to <=10 g/dL, or 1 mg if >10 g/dL; reduce starting dose by half with moderate hepatic impairment (Child-Pugh Class B) or concomitant moderate CYP2C8 inhibitor; maximum dose 24 mg once daily.
Anemia in chronic kidney disease (switching from ESA, on dialysis) Once daily oral; starting dose 4 mg for prior epoetin alfa <=2,000 units/week equivalent, 6 mg for >2,000 to <10,000, 8 mg for >=10,000 to <20,000, or 12 mg for >=20,000 units/week; reduce starting dose by half with moderate hepatic impairment or concomitant moderate CYP2C8 inhibitor; maximum dose 24 mg once daily.
Contraindications
- Uncontrolled hypertension
- Pure red cell aplasia (PRCA) beginning after treatment with Mircera or other erythropoietin protein drugs
- Serious or severe allergic reactions to Mircera (e.g., anaphylactic reactions, angioedema, bronchospasm, skin rash, urticaria)
- Concomitant use of a strong CYP2C8 inhibitor (e.g., gemfibrozil)
- Uncontrolled hypertension
Adverse Reactions
Most common (>=5%) Hypertension, diarrhea, nasopharyngitis, upper respiratory tract infection, headache, muscle spasms, procedural hypotension, fluid overload, vomiting, back pain, cough, arteriovenous fistula thrombosis, arteriovenous fistula site complication, constipation, hypotension, urinary tract infection, pain in extremity
Serious Increased mortality, myocardial infarction, stroke, thromboembolism, tumor progression, hypertension, seizures, pure red cell aplasia, serious allergic reactions, severe cutaneous reactions
Postmarketing Stevens-Johnson syndrome/toxic epidermal necrolysis, pure red cell aplasia (PRCA)
Most common (>=10%) Hypertension, thrombotic vascular events, abdominal pain
Serious Death, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, heart failure hospitalization, hypertension, gastrointestinal erosion
Pharmacology
Mircera is a PEGylated erythropoietin receptor activator with greater in vivo activity and longer half-life than endogenous erythropoietin; it stimulates erythroid progenitor cells to increase red blood cell production, correcting the erythropoietin deficiency that is the primary cause of anemia in CKD.
Daprodustat is a reversible inhibitor of HIF-PH1, PH2, and PH3, stabilizing HIF-1alpha and HIF-2alpha transcription factors and increasing transcription of HIF-responsive genes including erythropoietin, thereby stimulating red blood cell production in a dose-dependent manner.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Mircera
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Jesduvroq
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (4/12) · Qty limit (0/12)
UnitedHealthcare
Mircera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Jesduvroq
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Mircera
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Jesduvroq
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Mircera.
No savings programs available for Jesduvroq.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MirceraView full Mircera profile
JesduvroqView full Jesduvroq profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.